Skip to main content
Premium Trial:

Request an Annual Quote

Rubicon Inks Distribution Deals in Europe, Asia-Pacific, Middle East

NEW YORK (GenomeWeb News) – Rubicon Genomics today announced several distribution deals for its nucleic acid library preparation products in Europe, the Asia-Pacific region, and the Middle East.

The Ann Arbor, Mich.-based firm has signed deals with Amplitech to distribute its products in France; HPST for the Czech Republic; and LuBio Science for Switzerland. In Asia agreements were reached with Recenttec covering Japan; Prisma Biotech for Taiwan, and S.M. Chemical for Thailand, while in Australia and New Zealand Custom Science will be a Rubicon distributor.

Lastly, in Qatar Rubicon said an unidentified local biomedical distributor will be supporting the firm's sales.

Financial and other terms of the deals were not disclosed.

In a statement, Rubicon CEO James Koziarz said the agreements extend his company's "reach in growing sequencing markets around the globe and enable our customers to access our products without the additional cost and complications of shipping from the US to global destinations."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.